Markers for prostate cancer
US6972170B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 10, 1999 |
| Grant date | Dec 6, 2005 |
| Priority date | — |
| Expiry date | Jun 10, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/118
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a method for determining the aggressiveness of a prostate carcinoma comprising: (a) obtaining a sample of the prostate carcinoma; and (b) detecting the presence of p27 protein in the prostate carcinoma, the absence of p27 indicating that the prostate carcinoma is aggressive. This invention also provides a method for diagnosing a beign prostate hyperplasia comprising: (a) obtaining an appropriate sample of the hyperplasia; and (b) detecting the presence of the p27 RNA, a decrease of the p27 RNA indicating that the hyperplasia is beign. This invention provides various uses of p27 in prostate cancer. Finally, this invention also provides different marker for prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.